Evidence map›Paper›PMID 41351276›Full record

Trial reportClinical and translational science2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long-Acting FGF21 Analog Zalfermin.

Kirsten Dahl, Martin Haljeta Friedrichsen, Rasmus Ribel-Madsen, Jakob Schiøler Hansen, Jesper Ole Clausen, Mads Axelsen, Mads Sundby Palle, Solvej Lund Lippert, Olle Björkdahl, Søren Toubro and 2 more

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kirsten DahlNovo Nordisk A/S, Bagsværd, Denmark.ORCID 0000-0001-5063-1554
Martin Haljeta FriedrichsenNovo Nordisk A/S, Bagsværd, Denmark.
Rasmus Ribel-MadsenNovo Nordisk A/S, Bagsværd, Denmark.
Jakob Schiøler HansenNovo Nordisk A/S, Bagsværd, Denmark.
Jesper Ole ClausenNovo Nordisk A/S, Bagsværd, Denmark.
Mads AxelsenGubra A/S, Hørsholm, Denmark.
Mads Sundby PalleNovo Nordisk A/S, Bagsværd, Denmark.ORCID 0009-0000-7127-2861
Solvej Lund LippertNovo Nordisk A/S, Bagsværd, Denmark.
Olle BjörkdahlNovo Nordisk A/S, Bagsværd, Denmark.
Søren ToubroNovo Nordisk A/S, Bagsværd, Denmark.
Cassandra KeyICON Early Phase Service, San Antonio, Texas, USA.
Birgitte AndersenNovo Nordisk A/S, Bagsværd, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This first-in-human study investigated the safety, pharmacokinetics, and pharmacodynamics of the long-acting fibroblast growth factor 21 (FGF21) analog zalfermin. Healthy male participants (n = 56) with body mass index 25.0-34.9 kg/m

Indexed as

Fibroblast Growth FactorsAdultDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersHumansInjections, SubcutaneousMaleMiddle AgedYoung AdultFGF21 protein, humanfibroblast growth factor 21Fibroblast Growth Factorsadverse drug reactionsadverse eventsethnicitylivermetabolismobesitypharmacodynamicspharmacokineticspharmacologyphase I

Identifiers

PMID41351276
PMCPMC12680786

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.